Plasma resistin levels in asthmatics as a marker of disease state

Journal of Asthma

Volumn 44, Issue 7, 2007, Pages 509-513

  LaRochelle, Jeffrey ^a,b   Freiler, John ^a   Dice, John ^a   Hagan, Larry ^a  

^a WILFORD HALL MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

Asthma; CRP; Diabetes; FIZZ; Resistin

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; GLUCOSE; RESISTIN;

ADULT; AGED; ARTICLE; ASTHMA; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION;

ADOLESCENT; ADULT; AGED; ASTHMA; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; COHORT STUDIES; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; RESISTIN; SEVERITY OF ILLNESS INDEX;

EID: 34548849526     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.1080/02770900701495785     Document Type: Article

References (34)

1. FastStats A to Z: asthma. Available at: http://www.cdc.gov/nchs/fastats/ asthma.htm. Accessed 15 Jan 2006.
2. Asthma in America Survey, Executive Summary. Available at: http://www.asthmainamerica.com/aaa_index.html. Accessed 15 Jan 2006.
3. Asthma in America Survey, Executive Summary. Available at: http://www.asthmainamerica.com/slides/slide20.htm. Accessed 15 Jan 2006.
4. Leuppi JD, Salome CM, Jenkins CR, Anderson SD, Xuan W, Marks GB, Koskela H, Brannan JD, Freed R, Andersson M, Chan HK, Woolcock AJ. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am J Respir Crit Care Med 2001; 163:406-412.
5. Deykin A, Lazarus SC, Fahy JV, Wechsler ME, Boushey HA, Chinchilli VM, et al. Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids. J Allergy Clin Immunol 2005; 115:720-727.
6. Bousquet J, Chanez P, Lacoste JY, Barneon G, Ghavanian N, Enander I, et al. Eosinophilic inflammation in asthma. N Engl J Med 1990; 323:1033-1039.
7. Jatakanon A, Lim S, Barnes PJ. Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med 2000; 161:64-72.
8. Jatakanon A, Lim S, Kharitonov SA, Chung KF, Barnes PJ. Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. Thorax 1998; 53:91-95.
9. Jeffrey PK, Wardlaw AJ, Nelson FC, Collins JV, Kay AB. Bronchial biopsies in asthma. An ultrastructural, quantitative study and correlation with hyperreactivity. Am Rev Respir Dis 1989; 140:1745-1753.
10. Saraiva-Romanholo BM, Barnabe V, Carvalho AL, Martins MA, Saldiva PH, Nunes Mdo P. Comparison of three methods for differential cell count in induced sputum. Chest 2003; 124:1060-1066.
11. Vints AM, Oostveen E, Eeckhaut G, Smolders M, De Backer WA. Time-dependent effect of nitrate-rich meals on exhaled nitric oxide in healthy subjects. Chest 2005; 128:2465-2470.
12. McTernan PG, Fisher FM, Valsamakis G, Chetty R, Harte A, McTernan CL, et al. Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipoctyes. J Clin Endocrinol Metab 2003; 88:6098-6106.
13. Steppan CM, Brown EJ, Wright CM, Baht S, Banerjee RR, Dai Cy, et al. A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci USA 2001; 98:502-506.
14. Hartman HB, Hu X, Tyler KX, Dalal CK, Lazar MA. Mechanisms regulating adipocyte expression of resistin. J Biol Chem 2002; 277:19754-19761.
15. Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, et al. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: Cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 2003; 88:4848-4856.
16. Nagaev I, Smith U. Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun 2001; 285:561-564.
17. Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, et al. Resistin is expressed in human macrophages and directly regulated by PPARγ activators. Biochem Biophys Res Commun 2003; 300:472-476.
18. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, et al. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-[gamma] action in humans. Diabetes 2001;50:2199-2202.
19. Youn BS, Yu KY, Park HJ, Lee NS, Min SS, Youn YM, et al. Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. J Clin Endocrinol Metab 2004; 89:150-156.
20. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, et al. A central role for JNK in obesity and insulin resistance. Nature 2002; 420:333-336.
21. Holcomb IN, Kabakoff RC, Chan B, Baker TW, Gurney A, Henzel W, et al. FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J 2000; 19:4046-4055.
22. Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Imai Y, et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 2004; 314:415-419.
23. Lu SC, Scieh WY, Chen CY, Hsu SC, Chen HL. Lipopolysaccharide increases resistin gene expression in vivo and in vitro. FEBS Lett 2002;530:158-162.
24. Rajala MW, LinY, Ranalletta M. Cell type-specific expression and coregulation of murine molecule-α in adipose tissue. Mol Endocrinol 2002; 16:1920-1930.
25. Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, Ehtesham NZ. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochem Biophys Res Commun 2005; 334:1092-1101.
26. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001; 293:1673-1677.
27. McTernan PG, McTernan CL, Chetty R, Jenner K, Fisher FM, Lauer MN, et al. Increased resistin gene and protein expression in human abdominal adipose tissue. J Clin Endocrinol Metab 2002; 87:2407-2410.
28. DeBrosse CW, Zimmermann N, King NE, Pope SM, Fulkerson PC, Mishra A, et al. C2 induction of resistin-like molecule beta (relm-beta) by respiratory allergen, IL-4, IL-13 and stat6 in experimental asthma. J Allergy Clin Immunol 2003; 111:901.
29. Guidelines for the diagnosis and management of asthma. National Heart, Lung, and Blood Institute. National Asthma Education Program. Expert Panel Report 2. Bethesda (MD): National Institutes of Health; 1997, NIH publication 97-4051.
30. NHLBI/WHO Workshop Report. Global strategy for asthma management and prevention. Global initiative for asthma. Bethesda (MD): National Institutes of Health; 1995. NIH publication 95-3659.
31. Jousilahti P, Salomaa V, Hakala K, Rasi V, Vahtera E, Palosuo T. The association of sensitive systemic inflammatory markers with bronchial asthma. Ann Allergy Asthma Immunol 2002; 89:381-385.
32. Humbles AA, Lu B, Nilsson CA, Lilly C, Israel E, Fujiwara Y, et al. A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature 2000; 406:998-1001.
33. Krug N, Tschernig T, Erpenbeck VJ, Hohlfeld JM, Kohl J. Complement factors C3a and C5a are increased in bronchoalveolar lavage fluid after segmental allergen provocation in subjects with asthma. Am J Respir Crit Care Med 2001; 164:1841-1843.
34. Nakano Y, Morita S, Kawamoto A, Suda T, Chida K, Nakamura H. Elevated complement C3a in plasma from patients with severe acute asthma. J Allergy Clin Immunol 2003; 112:525-530.